Corona vaccine: US biotech firm claims, says human trial successful
Coronavirus Vaccine Update: US biotech firm Inovio claims to have found encouraging results during testing of the corona virus vaccine. The firm claimed that the vaccine named INO-4800 was 94% successful during the trials conducted on 40 people.
Highlights
- US drug firm Innovio claims – the human trial of corona virus vaccine successful
- The company said – Vaccine gave 94% result during trial
- DNA based vaccine will make corona misleading protein in the body
Scientists are working day and night to vaccine this global epidemic to save the world suffering from the havoc of the Coronavirus. Scientists in many countries have also claimed that they have made the coronavirus vaccine. However, according to the World Health Organization, no such vaccine has yet been made, which can be called the coronavirus vaccine.
94 percent success claim
Meanwhile, the US biotech firm Inovio has claimed that there have been encouraging results during the testing of the corona virus vaccine. The firm claimed that the vaccine named INO-4800 was 94% successful during the trials conducted on 40 people.
Vaccine increased immunity
40 people between the ages of 18 and 50 were vaccinated in the US during clinical trials. These people were given two injections of the vaccine in four weeks. Test results showed that the INO-4800 vaccine enhanced immunity in the body of all people. According to the company, no adverse effects of the vaccine were seen during this period.
DNA vaccine is made from genetic code
According to Kate Broadrick, senior vice president of Innovio Company, on January 10, Chinese researchers released the genetic code of the corona virus, and the team coded the sequence with software and formulated the formula. This DNA vaccine will detect the spike protein of the coronavirus and mislead the virus by producing similar proteins. After this, as soon as the virus gets closer to that protein, it will be inactivated by the effect of the vaccine.
Corona will eliminate spike protein
Spike protein will develop immunity in the human body. If the spike protein is produced by the vaccine, then the body will consider it as a virus and make a greater number of antibodies. While this protein will not cause any harm to the body. While the corona virus will end.
In 13 vaccine clinical trial phase worldwide
Let us know that at present there are more than 120 participants working on the coronavirus vaccine. However, 13 of these vaccines have reached the clinical trial phase. The maximum of these is in China’s vaccine human trial. Let us know that 5 in China, 2 in the UK, 3 in the US, Russia in Australia, and Germany 1-1 vaccine is in the clinical trial phase.
How long will the vaccine come in the market
Once the three-phase human trial is successful, it will be given to the concerned country’s Drug Regulatory Commission for investigation. After which the government of that country will study all the aspects related to the vaccine closely. During this time it will be seen whether the vaccine has any ill effects on humans. Only after which this vaccine will be approved for production. This process takes an average of 3 to 4 months.
There are no comments at the moment, do you want to add one?
Write a comment